Caribou Biosciences, Inc. CRBU

Nasdaq · Phase 1 · oncology · cell therapy · EDGAR · Updated Nov 6, 2026

Caribou Biosciences, Inc. (Nasdaq: CRBU) is an oncology drug developer. Its lead program, vispacabtagene regedleucel (vispa-cel), is in Phase 1.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Program	Indication	Modality	Stage
vispacabtagene regedleucel (vispa-cel)	—	cell therapy	Phase 1
CB-011	—	cell therapy	Phase 1

Oct 2, 2026
discontinued Caribou plans to discontinue vispa-cel allogeneic CAR-T cell therapy program despite being pivotal trial-ready.Vispa-cel is pivotal trial-ready, with FDA alignment already reached on the phase 3 clinical trial design. Filing
Oct 2, 2026
discontinued Caribou plans to discontinue CB-011 allogeneic CAR-T cell therapy program for relapsed or refractory multiple myeloma.Caribou plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. Filing
Oct 2, 2026
discontinued Caribou plans to discontinue further development activities for vispa-cel allogeneic CAR-T cell therapy program.Caribou plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs, vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. Filing

2 more on record.

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export